Drug Profile
Thymalfasin pegol
Alternative Names: PEG-TA 1; PEG-Talpha1; PEG-thymalfasin; PEG-thymosin alpha 1; Pegylated thymalfasin - Jiangsu Hansoh Pharmaceutical; Pegylated thymosin alpha 1; Polyethylene glycol thymalfasin; Polyethylene glycol thymosin alpha1; Thymosin alpha pegolLatest Information Update: 05 Sep 2017
Price :
$50
*
At a glance
- Originator Jiangsu Hansoh Pharmaceutical
- Developer Jiangsu Hansoh Pharmaceutical; Nanjing Medical University
- Class Antineoplastics; Antivirals; Oligopeptides; Polyethylene glycols; Thymus hormones
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 05 Sep 2017 Discontinued - Phase-III for Hepatitis B (Combination therapy) in China (SC) (Jiangsu Hansoh Pharmaceutical pipeline, September 2017)
- 01 Aug 2013 Phase-III clinical trials in Hepatitis B (Combination therapy) in China (SC)